Suppr超能文献

用于肠道寡肽转运体的模型前药:模型药物在水溶液和各种生物介质中的释放

Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media.

作者信息

Nielsen C U, Andersen R, Brodin B, Frokjaer S, Steffansen B

机构信息

Department of Pharmaceutics, The Royal Danish School of Pharmacy, 2-Universitetsparken, DK-2100, Copenhagen, Denmark.

出版信息

J Control Release. 2001 May 18;73(1):21-30. doi: 10.1016/s0168-3659(01)00233-4.

Abstract

The human intestinal di/tri-peptide carrier, hPepT1, has been suggested as a target for increasing intestinal transport of low permeability compounds by creating prodrugs designed for the transporter. Model ester prodrugs using the stabilized dipeptides D-Glu-Ala and D-Asp-Ala as pro-moieties for benzyl alcohol have been shown to have affinity for hPepT1. Furthermore, in aqueous solution at pH 5.5 to 10, the release of the model drug seems to be controlled by a specific base-catalyzed hydrolysis, indicating that the compounds may remain relatively stable in the upper small intestinal lumen with a pH of approximately 6.0, but still release the model drug at the intercellular and blood pH of approximately 7.4. Even though benzyl alcohol is not a low molecular weight drug molecule, these results indicate that the dipeptide prodrug principle is a promising drug delivery concept. However, the physico-chemical properties such as electronegativity, solubility, and log P of the drug molecule may also have an influence on the potential of these kinds of prodrugs. The purpose of the present study is to investigate whether the model drug electronegativity, estimated as Taft substitution parameter (sigma*) may influence the acid, water or base catalyzed model drug release rates, when released from series of D-Glu-Ala and D-Asp-Ala pro-moieties. Release rates were investigated in both aqueous solutions with varying pH, ionic strength, and buffer concentrations as well as in in vitro biological media. The release rates of all the investigated model drug molecules followed first-order kinetics and were dependent on buffer concentration, pH, ionic strength, and model drug electronegativity. The electronegativity of the model drug influenced acid, water and base catalyzed release from D-Asp-Ala and D-Glu-Ala pro-moieties. The model drug was generally released faster from D-Asp-Ala- than from the D-Glu-Ala pro-moieties. In biological media the release rate was also dependent on the electronegativity of the model drug. These results demonstrate that the model drug electronegativity, estimated as Taft (sigma*) values, has a significant influence on the release rate of the model drug.

摘要

人肠道二/三肽转运体hPepT1被认为是一个靶点,可通过设计针对该转运体的前药来增加低渗透性化合物的肠道转运。已证明,以稳定二肽D-谷氨酸-丙氨酸和D-天冬氨酸-丙氨酸作为苯甲醇的前体部分的模型酯前药对hPepT1具有亲和力。此外,在pH 5.5至10的水溶液中,模型药物的释放似乎受特定的碱催化水解控制,这表明这些化合物在pH约为6.0的上段小肠腔中可能保持相对稳定,但仍会在细胞间和血液pH约为7.4时释放模型药物。尽管苯甲醇不是低分子量药物分子,但这些结果表明二肽前药原理是一种很有前景的药物递送概念。然而,药物分子的物理化学性质,如电负性、溶解度和脂水分配系数(log P)也可能对这类前药的潜力产生影响。本研究的目的是调查当从一系列D-谷氨酸-丙氨酸和D-天冬氨酸-丙氨酸前体部分释放时,作为塔夫脱取代参数(sigma*)估算的模型药物电负性是否会影响酸、水或碱催化的模型药物释放速率。在不同pH、离子强度和缓冲液浓度的水溶液以及体外生物介质中研究了释放速率。所有研究的模型药物分子的释放速率均符合一级动力学,且取决于缓冲液浓度、pH、离子强度和模型药物电负性。模型药物的电负性影响从D-天冬氨酸-丙氨酸和D-谷氨酸-丙氨酸前体部分的酸、水和碱催化释放。模型药物通常从D-天冬氨酸-丙氨酸前体部分的释放速度比从D-谷氨酸-丙氨酸前体部分快。在生物介质中,释放速率也取决于模型药物的电负性。这些结果表明,作为塔夫脱(sigma*)值估算的模型药物电负性对模型药物的释放速率有显著影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验